Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy.

Abstract

Immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1) are increasingly used to treat several malignancies, with the most common adverse event being cutaneous toxicity. We report the case of a 68-years-old man with stage IV non-small cell lung cancer treated with nivolumab who developed a pruritic, lichenoid eruption refractory to treatment with topical or systemic steroids, who was started on narrow band ultraviolet B therapy which resolved the reaction.

• Authors: Marie Donaldson, Joshua L Owen, Young K Chae, Jennifer N Choi
• Journal: Frontiers in oncology (Front Oncol) Vol. 8 Pg. 405 ( 2018) ISSN: 2234-943X [Print] Switzerland
• PMID: 30319970 (Publication Type: Case Reports)